Abstract
Background
Prolactin-secreting pituitary adenomas in childhood and adolescence are rare. First-line therapy consists of dopamine agonists (DAs) like cabergoline. Experience in treating prolactinomas in paediatric and adolescent patients is limited.
Methods
This study was a retrospective analysis of clinical data, laboratory data, radiological findings and medical treatment of paediatric and adolescent patients with prolactinomas between 2009 and 2018.
Results
Our cohort of nine patients had a median age at diagnosis of 13 years (range 5–17). Main presenting symptoms were weight gain, disorders of the pituitary-gonadal axis and headache. Treatment with cabergoline resulted in a marked reduction in prolactin concentration in all nine patients. Tumour mass reduction was confirmed by magnetic resonance imaging (MRI) scan in seven patients. Noteworthy is that cabergoline therapy triggered frequent adverse effects in a total of eight patients – seven of whom suffered from mental disorders, five of whom had neurological symptoms and five of whom had gastrointestinal problems. The adverse effects occurred at a median dose of only 0.5 mg/week (range 0.25–2.0). Most symptoms were alleviated after the cabergoline dose was lowered. Therapy discontinuation was not necessary in any patient.
Conclusions
Cabergoline effectively lowers prolactin levels and may reduce tumour mass in paediatric and adolescent patients with prolactinomas. Potential adverse effects may include mental disorders and behavioural problems even at low cabergoline doses. Low starting doses and careful individual dose adjustments are required to enable therapy adherence.
Acknowledgments
We thank Carole Cürten for proofreading our manuscript.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 2008;8:563–74.10.1586/14737175.8.4.563Search in Google Scholar PubMed PubMed Central
2. Colao A, Loche S. Prolactinomas in children and adolescents. In: Loche S, Cappa M, Ghizzoni L, Maghnie M, Savage MO, editors. Endocrine development. Basel: Karger, 2009:146–59.Search in Google Scholar PubMed
3. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab 1999;84:4317–23.10.1210/jcem.84.12.6215Search in Google Scholar PubMed
4. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265–73.10.1111/j.1365-2265.2006.02562.xSearch in Google Scholar PubMed
5. Liu Y, Yao Y, Xing B, Lian W, Deng K, et al. Prolactinomas in children under 14. Clinical presentation and long-term follow-up. Childs Nerv Syst 2015;31:909–16.10.1007/s00381-015-2679-5Search in Google Scholar PubMed
6. Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, et al.. Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary 2009;12:186–9.10.1007/s11102-008-0149-8Search in Google Scholar PubMed
7. Cannavò S, Venturino M, Curtò L, De Menis E, D’Arrigo C, et al. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf) 2003;58:519–27.10.1046/j.1365-2265.2003.01748.xSearch in Google Scholar PubMed
8. Steele CA, MacFarlane IA, Blair J, Cuthbertson DJ, Didi M, et al. Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes. Eur J Endocrinol 2010;163:515–22.10.1530/EJE-10-0519Search in Google Scholar PubMed
9. Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenický P, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 2015;100:1177–86.10.1210/jc.2014-3670Search in Google Scholar PubMed
10. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273–88.10.1210/jc.2010-1692Search in Google Scholar PubMed
11. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904–9.10.1056/NEJM199410063311403Search in Google Scholar PubMed
12. De Sousa SM, Chapman IM, Falhammar H, Torpy DJ. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine 2016. DOI: 10.1007/s12020-016-1088-1. Epub 2016 Sep 6.10.1007/s12020-016-1088-1Search in Google Scholar PubMed
13. Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, et al. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf) 2014;80:863–8.10.1111/cen.12375Search in Google Scholar PubMed PubMed Central
14. Noronha S, Stokes V, Karavitaki N, Grossman A. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 2016;51:205–10.10.1007/s12020-015-0727-2Search in Google Scholar PubMed
15. De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves: meta-analysis of observational studies. Herz 2013;38:868–80.10.1007/s00059-013-3816-0Search in Google Scholar PubMed
16. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23.10.1136/adc.45.239.13Search in Google Scholar PubMed PubMed Central
17. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.10.1136/adc.44.235.291Search in Google Scholar PubMed PubMed Central
18. Neuhauser H, Schienkiewitz A, Rosario AS, Dortschy R, Kurth B-M. Referenzperzentile für anthropometrische Maßzahlen und Blutdruck aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS). Robert Koch-Institut, 2013. DOI: 10.25646/3179. Available online at: https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsB/KiGGS_Referenzperzentile.pdf?__blob=publicationFile.Search in Google Scholar
19. Wiedemann G, Jonetz-Mentzel L. Establishment of reference ranges for prolactin in neonates, infants, children and adolescents. Eur J Clin Chem Clin Biochem J Forum Eur Clin Chem Soc 1993;31:447–51.10.1515/cclm.1993.31.7.447Search in Google Scholar
20. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84: 2518–22.10.1210/jcem.84.7.5810Search in Google Scholar PubMed
21. Hoffmann A, Adelmann S, Lohle K, Claviez A, Müller HL. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur J Pediatr 2018;177:125–32.10.1007/s00431-017-3042-5Search in Google Scholar PubMed
22. Bulwer C, Conn R, Shankar A, Ferrau F, Kapur S, et al. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clin Endocrinol (Oxf) 2017;86:862–4.10.1111/cen.13339Search in Google Scholar
23. Bilal L, Ching C. Cabergoline-induced psychosis in a patient with undiagnosed depression. J Neuropsychiatry Clin Neurosci 2012;24:E54.10.1176/appi.neuropsych.11110348Search in Google Scholar
24. Rovera C, Cremaschi L, Thanju A, Fiorentini A, Mauri MC, et al. Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report. Asian J Psychiatry 2016;22:94–5.10.1016/j.ajp.2016.05.010Search in Google Scholar
25. Pérez-Esparza R, Rojas-Guerrero CA, Andino-Rios GG, Arias-Garro P, Ramírez-Bermúdez J, et al. Clozapine treatment for cabergoline-induced psychosis in a patient with a giant prolactinoma. J Neuropsychiatry Clin Neurosci 2017;29:295–7.10.1176/appi.neuropsych.16110313Search in Google Scholar
26. Ali S, Miller KK, Freudenreich O. Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics 2010;51:370–6.10.1016/S0033-3182(10)70718-0Search in Google Scholar PubMed
27. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930.10.1001/jamainternmed.2014.5262Search in Google Scholar PubMed
28. Maiter D, Primeau V. 2012 Update in the treatment of prolactinomas. Ann Endocrinol 2012;73:90–8.10.1016/j.ando.2012.03.024Search in Google Scholar PubMed
29. Breil T, Lorz C, Choukair D, Mittnacht J, Inta I, et al. Clinical features and response to treatment of prolactinomas in children and adolescents: a retrospective single-centre analysis and review of the literature. Horm Res Paediatr 2018;89:157–65.10.1159/000486280Search in Google Scholar PubMed
30. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485–534.10.1210/er.2005-9998Search in Google Scholar PubMed
31. Eren E, Erdeve ŞS, Papatya Çakır ED, Ceylan LA, Sağlam H, et al. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 2011;3:65–9.10.4274/jcrpe.v3i2.14Search in Google Scholar PubMed PubMed Central
32. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, et al. Prolactinomas in children and adolescents. clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777–80.10.1210/jcem.83.8.5001Search in Google Scholar PubMed
33. Ji MJ, Kim JH, Lee JH, Lee JH, Kim YH, et al. Best candidates for dopamine agonist withdrawal in patients with prolactinomas. Pituitary 2017;20:578–84.10.1007/s11102-017-0820-zSearch in Google Scholar PubMed
© 2019 Walter de Gruyter GmbH, Berlin/Boston
